Bionano Genomics (MEX:BNGO) LT-Debt-to-Total-Asset : 0.06 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bionano Genomics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bionano Genomics's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.06.

Bionano Genomics's long-term debt to total assets ratio increased from Sep. 2023 (0.04) to Sep. 2024 (0.06). It may suggest that Bionano Genomics is progressively becoming more dependent on debt to grow their business.

Bionano Genomics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bionano Genomics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics LT-Debt-to-Total-Asset Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.27

0.02

0.03

Bionano Genomics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.03	0.04	0.05	0.06

Bionano Genomics LT-Debt-to-Total-Asset Calculation

Bionano Genomics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	121.79	/	3639.347
	=	0.03

Bionano Genomics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	103.984	/	1720.184
	=	0.06

Bionano Genomics (MEX:BNGO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bionano Genomics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BNGO:USA 0A4K:UK

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.